Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.

about

Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.

Item

http://www.wikidata.org/entity/Q39310587

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@en

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@nl

type

Item

label

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@en

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@nl

prefLabel

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@en

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@nl

P1476

Effect of bosutinib on the abs ...... ubstrate, in healthy subjects.

@en

P2093

Daniela Soriano Pignataro

http://www.w3.org/2001/XMLSchema#string

Kyle Matschke

http://www.w3.org/2001/XMLSchema#string

Poe-Hirr Hsyu

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-based design of novel potent nonpeptide thrombin inhibitors

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.

P2888

s00228-016-2115-0

P304

57-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-016-2115-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27717999

http://www.w3.org/2001/XMLSchema#string